NYSE:NVO

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading on Tuesday, extending gains after the Danish drugmaker began selling its once-daily Wegovy weight-loss pill in the United States. The stock was up at $57.29, compared with a prior close of $55.11. Public

6 January 2026

Health News·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly and Co shares fell on Monday and were last down 3.6% at $1,041.51 in after-hours trading. The stock weakened as rival Novo Nordisk began rolling out a pill version of its Wegovy weight-loss drug in the United States. The Washington Post

6 January 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.

5 January 2026

Health News·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session.

5 January 2026

NASDAQ:STTX·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session.

5 January 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares edged lower on Wednesday as investors weighed new signals that blockbuster diabetes and obesity drugs are heading into 2026 with lower price tags in some markets. The stock was down 0.1% at $1,078.95 by 1:48 p.m. ET, after trading between $1,076.86 and $1,083.25.

31 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Shares of Hims & Hers Health Inc fell 0.5% to $32.87 in premarket trading on Wednesday after closing down 3.1% at $33.04 in the prior session. The stock has traded between $23.97 and $72.98 over the past 52 weeks. Google

31 December 2025

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares were up 0.1% in after-hours trading on Tuesday at $1,079.75 after a Reuters report said it and Novo Nordisk are lowering prices of their top-selling obesity drugs in China. Reuters

30 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock dips after report flags China price cuts for Mounjaro

Eli Lilly and Company shares were down $1.73, or about 0.2%, at $1,077.00 in morning trading on Tuesday.

30 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk said it is lowering prices of its top-selling obesity drug Wegovy in China, after local outlet Yicai reported that list prices for the two highest doses were cut by 48% in the southwestern provinces of Yunnan and Sichuan. The new monthly list prices were 987 yuan and 1,284 yuan, Yicai said, citing local procurement authorities. Reuters

30 December 2025

NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

December 25, 2025 — Christmas Day is a market holiday in the U.S., but Novo Nordisk A/S is still doing what it’s done for most of the past two years: pulling attention toward anything labeled GLP‑1. NASDAQ Trader

25 December 2025

NYSE:NVO·Pharmaceuticals

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly and Company stock is in the spotlight on December 24, 2025 as investors digest a new round of GLP‑1 headlines that span regulatory momentum, global market expansion, and shifting coverage expectations—all of which feed directly into the long-term demand outlook for Lilly’s obesity and diabetes franchise.

24 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Dec. 24, 2025 — Novo Nordisk A/S has snapped back into the market’s spotlight this week after U.S. regulators cleared a pill version of its blockbuster obesity drug Wegovy—an approval that investors and analysts see as a pivotal moment in the fast-evolving GLP‑1 weight-loss race. But the story driving Novo Nordisk stock today is bigger than a single FDA decision: it’s also about pricing and coverage policy in the U.S., and a global expansion battle—especially in India—where branded GLP‑1s are colliding with the prospect of cheaper generics in 2026. Novo Nordisk+2Reuters+2

24 December 2025

Financial Forecasts·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly and Company ended Tuesday, December 23, 2025, modestly lower as investors digested a major competitive jolt in the booming obesity-drug market. LLY closed at $1,071.64, down about 0.45%, and was little changed in early after-hours trading. FinancialContent+1

23 December 2025

NYSE:LLY·NYSE:NVO·Stock Market

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

December 23, 2025 — Eli Lilly and Company stock is holding near record territory as investors digest a fresh twist in the weight-loss drug race: the FDA has cleared Novo Nordisk’s first oral version of Wegovy, intensifying competition right as Lilly pushes its own once-daily pill candidate, orforglipron, toward a potential 2026 approval.

23 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceutical Industry·Stock Market

Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

December 23, 2025 — Novo Nordisk A/S is back in the spotlight after U.S. regulators approved a pill version of Wegovy, a milestone that could reshape the fast-growing obesity drug market—and potentially reset the narrative around a stock that’s had a bruising 2025.

23 December 2025

NYSE:NVO·Pharmaceuticals

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

December 23, 2025 — Eli Lilly and Company is trading around $1,076 as investors digest a fresh competitive jolt in the obesity-drug race: the FDA has approved Novo Nordisk’s first daily oral version of Wegovy. The headline is about Novo, but the market’s real question is about Lilly’s moat: can LLY keep dominating the category while a new “pill era” starts to form? Reuters+1

23 December 2025

NYSE:LLY·NYSE:NVO·Wall Street Insights

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk A/S is back in the market’s spotlight on 23 December 2025 after a major regulatory milestone: the U.S. Food and Drug Administration approved a pill version of Wegovy, making it the first oral GLP‑1 receptor agonist cleared for chronic weight management in the U.S. The news sent Novo Nordisk shares sharply higher in early trading and reverberated across European markets, where the company’s move helped lift healthcare stocks. Novo Nordisk+2Reuters+2

23 December 2025

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” for chronic weight management—marking the first oral GLP‑1 authorized in the U.S. specifically for weight loss. Novo Nordisk+1

23 December 2025

Health News·NYSE:NVO·Pharmaceuticals

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly and Company ended Monday’s regular session higher — then slipped after the closing bell as investors digested a major late-day headline from its biggest obesity rival, Novo Nordisk.

23 December 2025

Earnings·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

NYSE:NVO 23 December 2025 - 6 January 2026